Cancer drug duo trial halted after just one patient
NCT ID NCT06006923
Summary
This study aimed to test whether adding the drug regorafenib to the approved immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced colorectal cancer that has specific genetic features (called MSI-H). The trial was designed to first check safety and early signs of effectiveness in a small group, then expand to a larger comparison. However, the study was terminated after enrolling only one participant, so no results are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.